Using rifapentine to prevent tuberculosis in various populations
Official title: Short-course rifapentine for TB prevention for all: clinical pharmacology matters
Funded at Vanderbilt University Medical Center · NIH-11006936 · Data updated 2026-11-12
This study is looking at how well a short treatment with rifapentine can help prevent tuberculosis in people who are at higher risk, like children, pregnant women, and those living with HIV, to make sure the treatment is safe and works effectively for them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | August 7, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $843,516 |
| NIH project number | 1R37AI184117-01A1 |
| Project ID | NIH-11006936 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children under 12 years old, pregnant women, and individuals living with HIV who are taking dolutegravir.
✕Less likely to help
Patients who are not in the specified high-risk groups or those not taking dolutegravir may not benefit from this research.
What this research studies
This research investigates the effectiveness of a short-course treatment using rifapentine to prevent tuberculosis (TB) in high-risk groups, including children, pregnant women, and people living with HIV. The study aims to determine the optimal dosing of rifapentine and other TB medications through pharmacokinetic assessments, ensuring that these treatments are safe and well-tolerated. By enrolling participants from these priority populations, the research seeks to confirm that the treatment achieves the necessary drug exposure levels for effective prevention. The approach includes careful monitoring and modeling to understand how different factors affect drug absorption and effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective TB prevention strategies for vulnerable populations.
How similar studies have gone: Previous research has shown promise in using rifapentine for TB prevention, but this specific approach focusing on high-risk populations is novel.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Dooley, Kelly E. — Vanderbilt University Medical Center
- Study coordinator: Dooley, Kelly E.
Related research
Other NIH-funded projects on the same topics.
-
Improving healthcare for patients with inherited cancer syndromes using a web-based platform
This study is testing a new online tool called MeTree that helps people understand their risk for inherited cancer by combining their medical records and family health history, making it easier for patients and doctors to get the information they need for better care and support.
-
Stroke prevention with hydroxyurea for children with sickle cell anemia in Nigeria
A multinational, patient-facing study tests whether hydroxyurea can safely prevent first strokes in Nigerian children with sickle cell anemia.
-
Scaling Up Task-Shifted Epilepsy Care for Children in Africa
A study to help children with epilepsy in Africa get diagnosed and receive seizure care through trained community health workers.
-
Enhanced surveillance for new vaccine‑preventable diseases
A Vanderbilt team is tracking how well vaccines work and how diseases like flu, RSV, norovirus, and SARS‑CoV‑2 affect young children over time.
-
Generative AI to create private, fair health data for research
A researcher at Vanderbilt aims to use Generative AI to create synthetic health data that protects patient privacy while helping AI models be fairer and more accurate.
-
ConProject-003: A patient-facing initiative at Vanderbilt for advancing care
A Vanderbilt-led project (ConProject-003) is funded to drive improvements in care for people with a specific health condition through a dedicated program.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.